› Forums › General Melanoma Community › SCH 727965- type of cyclin-dependent kinase inhibitors, anyone have any insight to this?
- This topic has 6 replies, 3 voices, and was last updated 13 years, 8 months ago by
FormerCaregiver.
- Post
-
- September 18, 2011 at 5:55 pm
My 54 year old father was diagnosed with Stage IV melanoma this past April after a tumor was discovered in his knee. He just finished up a 4 dose cycle of Yervoy- the FDA approved version, not a clinical trial. The scans just came back and he has new tumors and his current ones have continued to grow. His oncologist provided information about Dacarbazine and a new clinical trial with a drug called SCH 727965 which is in a new class of drugs caled cyclin-dependent kinase inhibitors. After reading the research consent form, I realize that the purpose of the
My 54 year old father was diagnosed with Stage IV melanoma this past April after a tumor was discovered in his knee. He just finished up a 4 dose cycle of Yervoy- the FDA approved version, not a clinical trial. The scans just came back and he has new tumors and his current ones have continued to grow. His oncologist provided information about Dacarbazine and a new clinical trial with a drug called SCH 727965 which is in a new class of drugs caled cyclin-dependent kinase inhibitors. After reading the research consent form, I realize that the purpose of the study is to establish a safe dosage and that it is a very new treatment. I was curious is anyone has had any experience with this trial or drug?
What have others next step been after Ipi did not work? That is the only treatment that he has recieved and it appears as though there are alot of other drugs/options out there. We just do not where to go from here, any advice would be greatly appreciated!
Thanks,
Meaghan
- Replies
-
-
- September 18, 2011 at 8:14 pm
1. He should get with a melanoma specialist – either referred by your oncologist or through one of the major centers (National Cancer Institute, MD Anderson). If it's growing and agressive after Ipi failure he should be prepared to travel and get to a facility that can try cutting edge treatments based on his particular make-up. IMO he should not just try the trial de jour his oncologist might have on offer – you want a trial that is as custom as possible for him.
2. He should be tested for and know his mutations (BRAF, HLA-2) – which will drive a lot of the type of clinical trial.
3. Go to clinicaltrials.gov and search for treatments based on location and mutation – read the inclusions and exclusions.
4. IL-2 after IPi (yervoy) seems promising, as does the TIL work (which utilizes your body's own white cells and reinjects them after lab replication, it also involves chemo and interleukin-2.
5. Get to a melanoma specialist.
Nick
-
- September 18, 2011 at 8:14 pm
1. He should get with a melanoma specialist – either referred by your oncologist or through one of the major centers (National Cancer Institute, MD Anderson). If it's growing and agressive after Ipi failure he should be prepared to travel and get to a facility that can try cutting edge treatments based on his particular make-up. IMO he should not just try the trial de jour his oncologist might have on offer – you want a trial that is as custom as possible for him.
2. He should be tested for and know his mutations (BRAF, HLA-2) – which will drive a lot of the type of clinical trial.
3. Go to clinicaltrials.gov and search for treatments based on location and mutation – read the inclusions and exclusions.
4. IL-2 after IPi (yervoy) seems promising, as does the TIL work (which utilizes your body's own white cells and reinjects them after lab replication, it also involves chemo and interleukin-2.
5. Get to a melanoma specialist.
Nick
-
- September 18, 2011 at 9:05 pm
Thanks for the advice Nick. He is seeing a melanoma specialist at Dana Farber and we do know he's BRAF negative. We have an appointment this coming Friday to discuss options including the trial that was offered. I'm trying to find out as much as I possibly can about any and every other options to discuss with his oncologist because as possibly promising as the trial could be, it is just very new. I'll definitely be inquiring about the IL-2 and TIL, thank you!
-Meaghan
-
- September 18, 2011 at 9:05 pm
Thanks for the advice Nick. He is seeing a melanoma specialist at Dana Farber and we do know he's BRAF negative. We have an appointment this coming Friday to discuss options including the trial that was offered. I'm trying to find out as much as I possibly can about any and every other options to discuss with his oncologist because as possibly promising as the trial could be, it is just very new. I'll definitely be inquiring about the IL-2 and TIL, thank you!
-Meaghan
-
- September 19, 2011 at 9:49 am
Welcome to our forum, Meaghan. I encourage you to fill in some details on the profile page for your father, as this will help us to help you better.
I am familiar with cyclin-dependent inhibitors in general, as my late wife was treated with one that is called P276-00. Unfortunately, it wasn't successful in practice although the theory sounded good. I haven't heard much about these inhibitors lately, so I wonder about their efficacy.
There are a number of treatments that may be suitable for your father, but a lot depends on his state of health and how much melanoma his body has to deal with.
Hope this helps.
Frank from Australia
-
- September 19, 2011 at 9:49 am
Welcome to our forum, Meaghan. I encourage you to fill in some details on the profile page for your father, as this will help us to help you better.
I am familiar with cyclin-dependent inhibitors in general, as my late wife was treated with one that is called P276-00. Unfortunately, it wasn't successful in practice although the theory sounded good. I haven't heard much about these inhibitors lately, so I wonder about their efficacy.
There are a number of treatments that may be suitable for your father, but a lot depends on his state of health and how much melanoma his body has to deal with.
Hope this helps.
Frank from Australia
-
- You must be logged in to reply to this topic.